{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:16:46Z","timestamp":1794266206773,"version":"4.9.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Erythropoietin (EPO) seems to have a good application prospect both in experimental models and patients with hypoxic ischaemic encephalopathy (HIE). Data regarding the effect of EPO on death or neurodevelopmental impairment are conflicting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A search was conducted by two investigators involved in this research in PubMed, Embase, and Cochrane databases for studies in English, in Wanfang, VIP, and Cnki databases for Chinese studies (all last launched on 2022\/08\/31). Ultimately, we identified 11 original studies, including the EPO group (<jats:italic>n<\/jats:italic>\u2009=\u2009636) and the control group (<jats:italic>n<\/jats:italic>\u2009=\u2009626). Odds ratio (OR) and weighted mean difference were calculated using a random effects or fixed effects model, depending on the data type and heterogeneity of the included studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1. The comparison of effectiveness of EPO treatment on HIE: (1) With respect to death, data showed no significant difference between EPO and control groups (OR\u2009=\u20090.97, 95% CI, 0.66\u20131.43; <jats:italic>P<\/jats:italic>\u2009=\u20090.88); Considering the additional effect of mild hypothermia treatment (MHT), no significant difference was found between EPO\u2009+\u2009MHT\/control\u2009+\u2009MHT groups either (OR\u2009=\u20091.09, 95% CI, 0.69\u20131.73; <jats:italic>P<\/jats:italic>\u2009=\u20090.72); With respect to the interference of different routes of medication administration, Meta-analysis further showed no difference between intravenous EPO\/control groups (OR\u2009=\u20091.13, 95% CI, 0.70\u20131.82; <jats:italic>P<\/jats:italic>\u2009=\u20090.62). (2) With respect to cerebral palsy, the analysis showed no significant difference (OR\u2009=\u20090.76, 95% CI, 0.50\u20131.15; <jats:italic>P<\/jats:italic>\u2009=\u20090.20); Considering the effect of MHT and routes of medication administration, data further showed no difference between EPO group and control group (OR\u2009=\u20091.26, 95% CI, 0.73\u20132.19; <jats:italic>P<\/jats:italic>\u2009=\u20090.41). (3) Regarding epilepsy, no significant difference was found (OR\u2009=\u20090.49, 95% CI, 0.20\u20131.19; <jats:italic>P<\/jats:italic>\u2009=\u20090.12). MR abnormality was less common in EPO group (OR\u2009=\u20090.39, 95% CI, 0.19\u20130.79; <jats:italic>P<\/jats:italic>\u2009=\u20090.008). 2. The comparison of possible adverse events of EPO: EPO treatment would not increase the risk of thrombocytopenia, hypotension, and hepatic and kidney injury.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis showed that EPO treatment is not beneficial for reducing death and improving neurological impairment, though it would not increase the risk of adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1074287","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:09:21Z","timestamp":1673366961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The effect of erythropoietin on neonatal hypoxic-ischemic encephalopathy: An updated meta-analysis of randomized control trials"],"prefix":"10.3389","volume":"10","author":[{"given":"Jing-Jing","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"106595","DOI":"10.1016\/j.envint.2021.106595","article-title":"Global, regional, and national burdens of ischemic heart disease and stroke attributable to exposure to long working hours for 194 countries, 2000\u20132016: a systematic analysis from the WHO\/ILO joint estimates of the work-related burden of disease and injury","volume":"154","author":"Pega","year":"2021","journal-title":"Environ Int"},{"key":"B2","first-page":"409","article-title":"No cry at birth: global estimates of intrapartum stillbirths and intrapartum-related neonatal deaths","volume":"83","author":"Lawn","year":"2005","journal-title":"Bull World Health Organ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.siny.2014.10.004","article-title":"Cooling in a low-resource environment: lost in translation","volume":"20","author":"Montaldo","year":"2015","journal-title":"Semin Fetal Neonatal Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S0002-9378(99)70676-9","article-title":"Newborn assessment and long-term adverse outcome: a systematic review","volume":"180","author":"van de Riet","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0146-0005(03)00047-8","article-title":"Challenge of conducting trials of neuroprotection in the asphyxiated term infant","volume":"4","author":"Shankaran","year":"2003","journal-title":"Semin Perinatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3969\/j.issn.1003-515X.2008.14.010","article-title":"Investigation of disease constitution of newborn infants in 52 hospitals in foshan city","volume":"23","author":"Gao","year":"2008","journal-title":"J Pract Pediatr Clin"},{"key":"B7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3969\/j.issn.1005-2224.2003.11.009","article-title":"Investigation on the incidence and early diagnosis of hypoxic-ischemic encephalopathy of neonates","volume":"18","author":"Dong","year":"2003","journal-title":"Chin J Prac Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/archpediatrics.2011.43","article-title":"Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial","volume":"165","author":"Jacobs","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa1112066","article-title":"Childhood outcomes after hypothermia for neonatal encephalopathy","volume":"366","author":"Shankaran","year":"2012","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1203\/01.PDR.0000169971.64558.5A","article-title":"Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia","volume":"58","author":"Demers","year":"2005","journal-title":"Pediatr Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1203\/pdr.0b013e3180332cec","article-title":"A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats","volume":"61","author":"Kellert","year":"2007","journal-title":"Pediatr Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1542\/peds.2008-3553","article-title":"Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy","volume":"124","author":"Zhu","year":"2009","journal-title":"Pediatrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1542\/peds.2009-2268","article-title":"Human recombinant erythropoietin in asphyxia neonatorum: pilot trial","volume":"125","author":"Elmahdy","year":"2010","journal-title":"Pediatrics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e20160191","DOI":"10.1542\/peds.2016-0191","article-title":"High-Dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial","volume":"137","author":"Wu","year":"2016","journal-title":"Pediatrics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1515\/jpm-2018-0360","article-title":"Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysis","volume":"47","author":"Razak","year":"2019","journal-title":"J Perinat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2119660","article-title":"Trial of erythropoietin for hypoxic-ischemic encephalopathy in newborns","volume":"387","author":"Wu","year":"2022","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00784-002-0188-x","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"7","author":"Moher","year":"2003","journal-title":"Clin Oral Investig"},{"key":"B19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/bmj.328.7441.702","article-title":"CONSORT Statement: extension to cluster randomised trials","volume":"328","author":"Campbell","year":"2004","journal-title":"Br Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jse.2013.01.017","article-title":"An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria","volume":"22","author":"McCormick","year":"2013","journal-title":"J Shoulder Elbow Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ped.12121","article-title":"High-dose phenobarbital or erythropoietin for the treatment of perinatal asphyxia in term newborns","volume":"55","author":"Avasiloaiei","year":"2013","journal-title":"Pediatr Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3109\/14767058.2013.855894","article-title":"Single dose recombinant erythropoietin versus moderate hypothermia for neonatal hypoxic ischemic encephalopathy in low resource settings","volume":"27","author":"El Shimi","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/jp.2017.17","article-title":"Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial","volume":"37","author":"Malla","year":"2017","journal-title":"J Perinatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3969\/j.issn.1006-5725.2021.01.012","article-title":"Efficacy and safety analysis of EPO combined with mild hypothermia in the treatment of moderate to severe HIE","volume":"37","author":"Li","year":"2021","journal-title":"J Pract Med"},{"key":"B27","first-page":"855","article-title":"Therapeutic effects of erythropoietin on hypoxic-ischemic encephalopathy in neonates","volume":"13","author":"Wang","year":"2011","journal-title":"Chin J Contemp Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3969\/j.issn.1673-5501.2015.02.002","article-title":"Safety observation of therapeutic hypothermia conjunction with erythropoietin injection in the treatment of term-neonatal hypoxic ischemic encephalopathy","volume":"10","author":"Lin","year":"2015","journal-title":"Chin J Evid-Based Med PediatrPediatrics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.7620\/zgfybj.j.issn.1001-4411.2019.09.36","article-title":"Effects of recombinant human erythropoietin on oxidative stress injury and neurobehavioral development in neonates with hypoxic-ischemic encephalopathy","volume":"34","author":"Lin","year":"2019","journal-title":"Matern Child Health J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14715\/cmb\/2022.68.4.5","article-title":"Effects of EPO combined with mild hypothermia on oxidative stress and neuroprotection in neonates with hypoxic-ischemic encephalopathy","volume":"68","author":"Xu","year":"2022","journal-title":"Cell Mol Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.31083\/j.jin.2020.03.4","article-title":"The effects of erythropoietin on neurogenesis after ischemic stroke","volume":"19","author":"Zhang","year":"2020","journal-title":"J Integr Neurosci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ijdevneu.2010.12.007","article-title":"Erythropoietin for neonatal brain injury: opportunity and challenge","volume":"29","author":"Xiong","year":"2011","journal-title":"Int J Dev Neurosci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1073\/pnas.051606598","article-title":"Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress","volume":"98","author":"Sir\u00e9n","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3109\/00207454.2014.989321","article-title":"Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases","volume":"125","author":"Merelli","year":"2015","journal-title":"Int J Neurosci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/apha.12313","article-title":"On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans","volume":"212","author":"Bailey","year":"2014","journal-title":"Acta Physiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.18926\/AMO\/31997","article-title":"Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants","volume":"55","author":"Akisu","year":"2001","journal-title":"Acta Med Okayama"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e00827","DOI":"10.1002\/brb3.827","article-title":"Erythropoietin regulates immune\/inflammatory reaction and improves neurological function outcomes in traumatic brain injury","volume":"7","author":"Zhou","year":"2017","journal-title":"Brain Behav"},{"key":"B39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.yexcr.2017.11.002","article-title":"Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR\/JAK2-STAT3 pathway","volume":"361","author":"Wei","year":"2017","journal-title":"Exp Cell Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3171\/2015.10.PEDS15554","article-title":"Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury","volume":"17","author":"Robinson","year":"2016","journal-title":"J Neurosurg Pediatr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1542\/peds.2003-1129-L","article-title":"Neurodevelopmental outcome and growth at 18\u201322 months\u2019 corrected age in extremely low birth weight infants treated with early erythropoietin and iron","volume":"114","author":"Ohls","year":"2004","journal-title":"Pediatrics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1542\/peds.2007-2591","article-title":"An approach to using recombinant erythropoietin for neuroprotection in very preterm infants","volume":"122","author":"Fauch\u00e8re","year":"2008","journal-title":"Pediatrics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1203\/pdr.0b013e31805341dc","article-title":"Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats","volume":"61","author":"Statler","year":"2007","journal-title":"Pediatr Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/pr.2017.15","article-title":"High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia","volume":"81","author":"Frymoyer","year":"2017","journal-title":"Pediatr Res"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1074287\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:09:32Z","timestamp":1673366972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1074287\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":44,"alternative-id":["10.3389\/fped.2022.1074287"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1074287","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1074287"}}